Anti-Toxoplasma gondii Activity of Curcumin: A Systematic Review of Pre-clinical Studies.

Q3 Pharmacology, Toxicology and Pharmaceutics

Infectious disorders drug targets Pub Date : 2023-01-01 DOI:10.2174/1871526522666220820185637

Hamed Kalani, Pegah Shakib, Roghiyeh Faridnia, Jeffery Ho, Omid Mardanshah, Mehrdad Dolatshah, Asghar Sepahvand, Kourosh Cheraghipour, Masoomeh Zivdaria

{"title":"Anti-Toxoplasma gondii Activity of Curcumin: A Systematic Review of Pre-clinical Studies.","authors":"Hamed Kalani, Pegah Shakib, Roghiyeh Faridnia, Jeffery Ho, Omid Mardanshah, Mehrdad Dolatshah, Asghar Sepahvand, Kourosh Cheraghipour, Masoomeh Zivdaria","doi":"10.2174/1871526522666220820185637","DOIUrl":null,"url":null,"abstract":"Objective: This study has focused on anti-Toxoplasma gondii activity of curcumin.Methods: In this systematic review, anti-parasitic activity of Curcuma longa on Toxoplasma gondii was assessed. Therefore, several databases, including PubMed, Scopus, Web of Science, Embase and Google Scholar, were searched from 2010 to 2020.Results: Of the 2200 papers retrieved between 2010 and 2020, six articles were reliable and were scrutinized. In 2 in vitro studies, the most used strain was the RH strain of Toxoplasma gondii, whereas among 4 in vivo studies, RH strain was found in 2 (50%) studies, Me49 strain in 1(25%) study, and RH and Me49 strain in 1 (25%) study. In four in vivo studies, the most used animal model was BALB/c, and Swiss albino was found in 1 study (25%) and Albino rats in 1 study (25%).Conclusion: Curcumin and nanoparticles formulated with curcumin are new and useful agents for the treatment of parasitic diseases and reduction of drug resistance. The success of this therapeutic approach stems from the specific action of Curcuma longa against parasites and pathogens.","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 2","pages":"e200822207821"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526522666220820185637","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study has focused on anti-Toxoplasma gondii activity of curcumin.

Methods: In this systematic review, anti-parasitic activity of Curcuma longa on Toxoplasma gondii was assessed. Therefore, several databases, including PubMed, Scopus, Web of Science, Embase and Google Scholar, were searched from 2010 to 2020.

Results: Of the 2200 papers retrieved between 2010 and 2020, six articles were reliable and were scrutinized. In 2 in vitro studies, the most used strain was the RH strain of Toxoplasma gondii, whereas among 4 in vivo studies, RH strain was found in 2 (50%) studies, Me49 strain in 1(25%) study, and RH and Me49 strain in 1 (25%) study. In four in vivo studies, the most used animal model was BALB/c, and Swiss albino was found in 1 study (25%) and Albino rats in 1 study (25%).

Conclusion: Curcumin and nanoparticles formulated with curcumin are new and useful agents for the treatment of parasitic diseases and reduction of drug resistance. The success of this therapeutic approach stems from the specific action of Curcuma longa against parasites and pathogens.

查看原文本刊更多论文

姜黄素抗刚地弓形虫活性的临床前研究综述

目的:研究姜黄素抗刚地弓形虫的活性。方法:系统评价姜黄对刚地弓形虫的抗寄生活性。因此，从2010年到2020年，我们检索了PubMed、Scopus、Web of Science、Embase和Google Scholar等数据库。结果:在2010 - 2020年间检索到的2200篇论文中，有6篇是可靠的，并经过了审查。在2项体外研究中，使用最多的是弓形虫RH株，而在4项体内研究中，2项(50%)研究中发现了RH株，1项(25%)研究中发现了Me49株，1项(25%)研究中发现了RH和Me49株。在4项体内研究中，使用最多的动物模型是BALB/c, 1项研究(25%)发现瑞士白化(Swiss albino)， 1项研究(25%)发现白化大鼠。结论:姜黄素及其纳米颗粒是治疗寄生虫病和降低耐药性的新型有效药物。这种治疗方法的成功源于姜黄对寄生虫和病原体的特殊作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.10

自引率

0.00%

发文量

123

期刊介绍： Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.